AKT1 and cancer: However, other antagonists and agonists present in the screen including the 5-HTR4 agonists (Cisparide) that did not have any anti-cancer effects further suggesting that TM is uniquely acting to distinctly target other molecules, likely upstream receptors or kinases of the PI3K/Akt/mTOR pathways.